Philippe Menu Sells 3,725 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

Key Points

• Philippe Menu sold 3,725 shares of SOPHiA GENETICS on April 10 at an average price of $4.68 under a pre-arranged Rule 10b5-1 plan to cover tax withholding, leaving him with 272,996 shares (a 1.35% reduction).
• Across trades from March 19 to April 13 he sold about 18,564 shares, generating roughly $88,800 in proceeds.
• SOPH trades near $4.96 with a market cap of ~$339.7M, reported a quarterly EPS miss (‑$0.28 vs. ‑$0.20) and remains unprofitable; analysts’ consensus rating is Hold with a target of $7.00.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Philippe Menu sold 3,725 shares of the business's stock in a transaction dated Friday, April 10th. The stock was sold at an average price of $4.68, for a total transaction of $17,433.00. Following the transaction, the insider owned 272,996 shares in the company, valued at approximately $1,277,621.28. This trade represents a 1.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Philippe Menu also recently made the following trade(s):

• On Monday, April 13th, Philippe Menu sold 4,400 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.76, for a total transaction of $20,944.00.
• On Thursday, April 9th, Philippe Menu sold 1,931 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total transaction of $9,152.94.
• On Wednesday, April 8th, Philippe Menu sold 2,800 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.84, for a total transaction of $13,552.00.
• On Tuesday, April 7th, Philippe Menu sold 2,400 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.87, for a total transaction of $11,688.00.
• On Monday, April 6th, Philippe Menu sold 2,700 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total transaction of $13,095.00.
• On Thursday, March 19th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.79, for a total transaction of $2,912.32.

SOPHiA GENETICS Price Performance

SOPH traded up $0.11 on Tuesday, hitting $4.96. 148,768 shares of the company were exchanged, compared to its average volume of 183,135. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.84 and a current ratio of 1.96. The business's fifty day moving average is $4.74 and its 200 day moving average is $4.71. SOPHiA GENETICS SA has a fifty-two week low of $2.58 and a fifty-two week high of $5.70. The firm has a market capitalization of $339.71 million, a P/E ratio of -9.73 and a beta of 1.04.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.08). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The company had revenue of $21.71 million for the quarter, compared to analyst estimates of $21.20 million. As a group, sell-side analysts anticipate that SOPHiA GENETICS SA will post -0.96 EPS for the current year.

Institutional Trading of SOPHiA GENETICS

Several institutional investors and hedge funds have recently modified their holdings of SOPH. Savvy Advisors Inc. purchased a new stake in shares of SOPHiA GENETICS in the third quarter valued at about $48,000. Squarepoint Ops LLC purchased a new stake in shares of SOPHiA GENETICS in the third quarter valued at about $49,000. Perkins Capital Management Inc. purchased a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at about $49,000. Quadrature Capital Ltd purchased a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at about $54,000. Finally, XTX Topco Ltd purchased a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at about $55,000. Hedge funds and other institutional investors own 31.59% of the company's stock.

Analyst Ratings Changes

Several brokerages have weighed in on SOPH. BTIG Research restated a "buy" rating and set a $7.00 target price on shares of SOPHiA GENETICS in a research report on Tuesday, March 3rd. Guggenheim upped their target price on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a "buy" rating in a research report on Monday, January 26th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, SOPHiA GENETICS currently has a consensus rating of "Hold" and a consensus target price of $7.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.